ERBB2 and colorectal carcinoma: In their first attempts to apply CAR T-cell therapy to CRC, several groups have conducted clinical trials to assess the anticancer activity of CAR T-cells directed against HER2, tumor-associated glycoprotein 72 (TAG-72), CEA, or CEACAM5 (33, 92, 145, 146).